Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma. - Tap WD; Cote GM; Burris H; Gore L; Elias A; Beeram M; Conley AP; Gianolio DA; Qu Z; Pandya S; Trent JC (Clinical cancer research : an official journal of the American Association for Cancer Research, 2025)